Xintela, Lund-based biomedical company working in the fields of regenerative medicine and cancer, has a new head of business development.

The role is assumed by Rickard Mossell, Xintela’s co-founder and presently the CEO of Ideon Innovation. Apart from business development and financing functions, Rickard will also be a member of Xintela’s management team. To understand how important is this role in a business, you can ask experts like Bob Bratt to explain you the fundamentals

Rickard Mosell’s acedemic background is in law and he has broad experience of innovation and business operations. Amongst other roles, he has been the CEO for Ideon Science Park in Lund – comprising approximately 370 companies with 2 700 employees – and his most recent appointment as CEO for the business incubator Ideon Innovation.

“It is vital for going forward that Xintela has a strong focus on business development, and we are confident that Rickard has the experience, the competence and the network needed. He has long been a driving force in business development, sales and communication and has built up an extensive and significant network, both nationally and internationally. We are very happy to welcome Rickard back to Xintela”, says the company’s CEO Evy Lundgren-Åkerlund.

Rickard Mosell has previously been closely involved with Xintela. In 2009, he was a co-founder of the company and thereafter, until 2014, a boardmemer.

“I am really looking forward to being a part of Xintela again and helping to develop a clear commercial focus for this exciting company. Of course it makes things easier that I already have a good understanding of the operations and that I know Evy previously”, says Rickard Mosell.

Xintela was founded in 2009 by Evy Lundgren-Åkerlund as a result of years of research and development that she and her team performed at Lund University together with a company Cartela.

In 2013 Xintela built up its research and development with a focus on developing stem cell products for the repair of damaged articular cartilage. In 2014 began a research and development to develop the treatment of certain brain tumors.

Xintela has a broad and strong patent portfolio that includes over 50 granted patents in key markets such as Australia, Europe, USA, Canada and Japan.